Posted on October 13, 2016 by Sitemaster
Just over 3 years ago, Bristol-Myers Squibb announced that treatment with ipilimumab (Yervoy) had failed to show a survival benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). For readers who may be interested, the data from this trial have finally been reported by Beer et al. in the Journal of Clinical Oncology.
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, ipilimumab, mCRPC, metastatic, outcome | 2 Comments »
Posted on February 26, 2015 by Sitemaster
Results from a small trial of Barvarian Nordic’s investigational drug Prostvac — used in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy) — appear to have shown relatively dramatic effects in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, ipilimumab, mCRPC, metastatic, Prostvac, Yervoy | 6 Comments »
Posted on May 8, 2013 by Sitemaster
Final data have just been reported on the results of a Phase I/II study of treatment with ipilimumab as monotherapy and in combination with radiotherapy in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE ..
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, ipilimumab, mCRPC, metastatic | Leave a comment »
Posted on February 23, 2012 by Sitemaster
A media release issued earlier today by Barvarian Nordic (the developer of Prostvac®) gives us an inkling of where we may be headed in the development of combination therapies for the management of late stage (and maybe even earlier stage) forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castrate-resistant, combination, immunotherapeutic, ipilimumab, mCRPC, outcome, Prostvac, survival | Leave a comment »
Posted on February 9, 2012 by Sitemaster
Has the clinical success of some new drugs started to affect enrollment in trials of others for advanced forms of prostate cancer? … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ipilimumab, TAK-700, tasquinimod, trials | Leave a comment »
Posted on May 20, 2011 by Sitemaster
Two drugs already approved in the US that either have been or may be used in the treatment of prostate cancer have now been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: denosumab, ipilimumab, Xgeva, Yervoy | 2 Comments »
Posted on March 25, 2011 by Sitemaster
The U.S. Food & Drug Administration today approved ipilimumab (brand name Yervoy®) for the treatment of patients with metastatic melanoma (an aggressive form of skin cancer). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: ipilimumab, Yervoy | 8 Comments »
Posted on March 22, 2011 by Sitemaster
Rumors are circulating the the U.S. Food & Drug Administration might approve ipilimumab within the next few days for the treatment of metastatic melanoma. This approval could also offer opportunities for men with some forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: approval, ipilimumab | 1 Comment »
Posted on February 18, 2011 by Sitemaster
At the Genitourinary Cancers Symposium yesterday afternoon, new data were presented from Phase II studies of tasquinimod and cabozatinib (XL184) … READ MORE …
Filed under: Drugs in development, Management | Tagged: cabozatinib, ipilimumab, tasquinimod, XL184 | 1 Comment »
Posted on January 3, 2011 by Sitemaster
Posted on June 5, 2010 by Sitemaster
One of the really “hot” pieces of news from ASCO today was the result of a Phase III clinical trial of ipilimumab in a form of metastatic skin cancer called melanoma. This is (perhaps) very important for prostate cancer patients. … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, ipilimumab | Leave a comment »
Posted on March 9, 2010 by Sitemaster
In June 2009 we reported on data suggesting that the monocolonal antibody ipilimumab appeared to be capable of “downstaging” more advanced forms of prostate cancer such that the patients became re-eligible for localized therapy with curative intent. It’s time for an update based on data presented at the Genitourinary Cancers Symposium last Friday and Saturday. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: advanced, down-stageing, ipilimumab, locallly advanced | Leave a comment »
Posted on June 20, 2009 by Sitemaster
According to a report on WebMD, presumably based on media information provided by the Mayo Clinic, two patients with relatively advanced stages of prostate cancer treated with the investigational drug ipilimumab have been put into what appears to be complete remission. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: androgen deprivation therapy, down-staging, ipilimumab, surgery | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 